Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
University of Nebraska
University of Nebraska
Technical University of Munich
Jinling Hospital, China
Zhongda Hospital
Fudan University
Alliance for Clinical Trials in Oncology
Zhejiang Cancer Hospital
AIO-Studien-gGmbH
Beijing Tsinghua Chang Gung Hospital
Shanghai Zhongshan Hospital
Alliance for Clinical Trials in Oncology
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Krankenhaus Nordwest
Case Comprehensive Cancer Center
Rigshospitalet, Denmark
Weill Medical College of Cornell University
University of Pisa
Georgetown University
Centre Hospitalier Universitaire de Besancon
AIO-Studien-gGmbH
IRCCS San Raffaele
Sun Yat-sen University
Jinling Hospital, China
Shanghai Zhongshan Hospital
Yonsei University
Sun Yat-sen University
Eastern Hepatobiliary Surgery Hospital
AHS Cancer Control Alberta
Memorial Sloan Kettering Cancer Center
Fudan University
Thrombosis Research Institute
IRCCS San Raffaele
Dana-Farber Cancer Institute
Yonsei University
Shanghai Jiao Tong University School of Medicine
Anhui Medical University
Trans Tasman Radiation Oncology Group
Royal Marsden NHS Foundation Trust
Nihon University
Northwestern University
Stanford University
Swiss Cancer Institute
IRCCS San Raffaele
IRCCS San Raffaele
Samsung Medical Center
Royal Marsden NHS Foundation Trust